Last reviewed · How we verify
NCT04871035: IPET-GBS
Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)
trial testing Immunoadsorption in GBS in 20 participants. Currently enrolling.
4 May 2025
Quick facts
| Lead sponsor | University of Ulm |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 28 April 2021 |
| Primary completion | 4 May 2025 |
| Estimated completion | 4 May 2025 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Immunoadsorption
- Plasma Exchange — full drug profile →
Conditions studied
- GBS — all drugs for GBS →
Sponsor
University of Ulm
Who can join
18 and older, any sex, with GBS. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an observations study evaluating safety and efficacy of immunoadsorption compared to plasma exchange in Guillain-Barré Syndrome.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04871035
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Immunoadsorption
Trials testing the same drug.
- NCT07316127 — Immunoadsorption in Autoimmune Long COVID · Phase 2 · recruiting
- NCT06922851 — Protein A Immunoadsorption in Dilated Cardiomyopathy (RPIA-DCM) · NA · recruiting
- NCT05710770 — Immunoadsorption in Patients With Chronic Fatigue Syndrome Including Patients With Post-COVID-19 CFS · NA · completed
- NCT05841498 — Immunoadsorption Study Mainz in Adults With Post-COVID Syndrome · NA · completed
- NCT04881682 — Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · Phase 2 · recruiting
Other University of Ulm trials
Trials by the same sponsor.
- NCT07436195 — Imprinting in Metabolic Diseases - Identifying Epigenetic Mechanisms in Human Gestational Diabetes Through Cell-free DNA · recruiting
- NCT07154524 — Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · recruiting
- NCT06877143 — Hypercaloric PEG Nutrition in ALS to Sustain Energy Homeostasis · NA · recruiting
- NCT06280079 — Ultra-high-caloric, Fatty Diet in ALS · NA · recruiting
- NCT06627348 — Hilotherapy for Prevention of Chemotherapy-induced Peripheral Polyneuropathy · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04871035 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Ulm
- Last refreshed: 8 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04871035.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing